Therapeutic combinations of oral administration of paclitaxel and P-gp inhibitors for treatment of cancer

The present invention relates to therapeutic combinations of oral administration of paclitaxel and a P-gp inhibitor for the treatment of cancer. The present application relates to a pharmaceutical combination of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are useful for treating cancer in a subject, and for reducing or preventing toxicity, allergic infusion reactions, and other negative outcomes caused by or associated with intravenous administration of paclitaxel (e.g., Taxol or paclitaxel formulated with Cremophor) treatment in a subject with cancer. 本发明涉及用于治疗癌症的口服给药紫杉醇和P-gp抑制剂的治疗组合。本申请涉及口服给药的紫杉醇和P-gp抑制剂的药物组合。药物组合适用于治疗受试者的癌症，和减小或防止毒性、过敏型输液反应和由患有癌症受试者的静脉给药紫杉醇(例如，Taxol®或用Cremophor®配制的紫杉醇)治疗引起或与其相关的其它负面结果。